The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States.
COVID-19
Coronavirus Infections
/ economics
Delivery of Health Care
/ economics
Disease Outbreaks
/ economics
Female
Health Care Costs
/ statistics & numerical data
Health Resources
/ economics
Hospital Costs
/ statistics & numerical data
Humans
Intensive Care Units
/ economics
Length of Stay
/ economics
Male
Monte Carlo Method
Pandemics
/ economics
Pneumonia, Viral
/ economics
United States
COVID-19
Coronavirus
Cost reduction
Costs and spending
Diseases
Economic burden
Health policy
Hospital costs
Intensive care units
Prescription drug costs
Value
cost
Journal
Health affairs (Project Hope)
ISSN: 1544-5208
Titre abrégé: Health Aff (Millwood)
Pays: United States
ID NLM: 8303128
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
24
4
2020
medline:
17
6
2020
entrez:
24
4
2020
Statut:
ppublish
Résumé
With the coronavirus disease 2019 (COVID-19) pandemic, one of the major concerns is the direct medical cost and resource use burden imposed on the US health care system. We developed a Monte Carlo simulation model that represented the US population and what could happen to each person who got infected. We estimated resource use and direct medical costs per symptomatic infection and at the national level, with various "attack rates" (infection rates), to understand the potential economic benefits of reducing the burden of the disease. A single symptomatic COVID-19 case could incur a median direct medical cost of $3,045 during the course of the infection alone. If 80 percent of the US population were to get infected, the result could be a median of 44.6 million hospitalizations, 10.7 million intensive care unit (ICU) admissions, 6.5 million patients requiring a ventilator, 249.5 million hospital bed days, and $654.0 billion in direct medical costs over the course of the pandemic. If 20 percent of the US population were to get infected, there could be a median of 11.2 million hospitalizations, 2.7 million ICU admissions, 1.6 million patients requiring a ventilator, 62.3 million hospital bed days, and $163.4 billion in direct medical costs over the course of the pandemic.
Identifiants
pubmed: 32324428
doi: 10.1377/hlthaff.2020.00426
pmc: PMC11027994
mid: NIHMS1981236
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
927-935Subventions
Organisme : NICHD NIH HHS
ID : R01 HD086011
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD086861
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD070725
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD086013
Pays : United States
Organisme : AHRQ HHS
ID : R01 HS023317
Pays : United States
Références
Influenza Other Respir Viruses. 2010 Mar;4(2):61-72
pubmed: 20167046
Vaccine. 2007 Jun 28;25(27):5086-96
pubmed: 17544181
Clin Infect Dis. 2008 Apr 15;46(8):1139-41
pubmed: 18444847
Expert Rev Anti Infect Ther. 2012 Oct;10(10):1139-52
pubmed: 23199400
Pharmacoeconomics. 2004;22(5):275-84
pubmed: 15061677
Am J Prev Med. 2010 Nov;39(5):e21-9
pubmed: 20965375
Intensive Care Med. 2017 Jul;43(7):980-991
pubmed: 28550403
J Urban Health. 2011 Oct;88(5):982-95
pubmed: 21826584
Chest. 2017 Apr;151(4):755-763
pubmed: 27663180
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
J Trauma Acute Care Surg. 2018 Jul;85(1):148-154
pubmed: 29958249
PLoS Negl Trop Dis. 2017 Apr 27;11(4):e0005531
pubmed: 28448488
Clin Microbiol Infect. 2013 Nov;19(11):1014-22
pubmed: 23800220
J Public Health Manag Pract. 2010 May-Jun;16(3):252-61
pubmed: 20035236
Health Aff (Millwood). 2011 Jun;30(6):1141-50
pubmed: 21653968
Vaccine. 2010 Jul 12;28(31):4875-9
pubmed: 20483192
J Public Health Manag Pract. 2012 May-Jun;18(3):233-40
pubmed: 22473116
Clin Infect Dis. 2004 Dec 1;39(11):1572-80
pubmed: 15578353
Pathog Glob Health. 2015 Feb;109(1):4-9
pubmed: 25578284
J Infect Dis. 2019 Aug 9;220(6):920-931
pubmed: 30544164
Am J Prev Med. 2010 Mar;38(3):247-57
pubmed: 20042311
J Infect Dis. 1999 Jan;179(1):25-30
pubmed: 9841818
J Intensive Care. 2016 Aug 11;4:56
pubmed: 27525106
J Manag Care Pharm. 2004 Nov-Dec;10(6):521-30
pubmed: 15548124
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930